Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

On this episode, Arnaud Lacoste, Chief Scientific Officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

Congratulations to the Volumetric team on their acquisition by 3D Systems!